EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sputum antimicrobial susceptibility patterns and clinical outcomes among adult Aboriginal Australians with bronchiectasis

Timothy Howarth, Angelou Castro, Debora Kirojan, Alison O'Connor, Stuart Campbell, Subash S Heraganahally iD

Therapeutic Advances in Respiratory Disease · 2026

DOI: 10.1177/17534666261480883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2026. Verfasst von Timothy Howarth und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health, Charles Darwin University, Darwin, NT, Australia. Hauptthemen laut MEDLINE: Bronchiectasis, Sputum, Anti-Bacterial Agents, Bacteria. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Thoracic Society of Australia and New Zealand (TSANZ) Robert Pierce Grant-In-Aid for Indigenous Lung Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prevalence of bronchiectasis among the adult Aboriginal Australians is high, estimated to be up to 19.4/1000 people, with associated higher morbidity and mortality. However, despite evidence to suggest that adult Aboriginal Australians have higher bronchiectasis disease burden, the knowledge surrounding sputum antimicrobial susceptibility data is sparce.

Objectives

To assess the sputum antimicrobial susceptibility patterns among adult Aboriginal patients with bronchiectasis in the Northern Territory of Australia.

Design

Retrospective study.

Method

Patients aged 18 years and over with sputum antimicrobial susceptibility results available between 2011-2020 during a respiratory related hospital admission (restricted to ICD J presentations) were included. The sputum samples were processed and antibacterial susceptibility reported as per recommended selective susceptibility testing guidelines.

Results

A total of 183 patients had positive sputum cultures. Of these, 167 had antimicrobial susceptibility tested. Antimicrobial resistance to at least one antibiotic was noted for Haemophilus spp. 12 (7%), Pseudomonas spp. 26 (15.4%), Streptococcus pneumoniae 18 (23.1%), Staphylococcus spp. 17 (47.2%) and Klebsiella spp. 8 (88.9%). The greatest frequency of antimicrobial resistance was recorded against Ampicillin for Haemophilus spp . (5.8%), Ceftazidime for Pseudomonas spp. (7.7%), Erythromycin for Streptococcus pneumoniae (20.5%), Flucloxacillin and Amoxycillin/Clavulanate for Staphylococcus spp. (27.8%) and Ampicillin for Klebsiella spp. (88.9%). Multi-antimicrobial resistance was recorded in 31 unique patients. In univariate logistic regression models advancing age was associated with increased odds for antimicrobial resistance for Haemophilus spp. and patients with multi-antimicrobial resistance recorded a higher hospitalisation rate (median 14 vs. 8), more hours in intensive care (median 225.5 vs. 131) and left upper lobe bronchiectasis (41.9 vs 20.4%). Although, statistically not significant, the overall mortality was higher among patients demonstrating multi-antimicrobial resistance, including younger age at death.

Conclusion

The results of this study may be of utility in advocating antimicrobial stewardship among adult Aboriginal/Indigenous patients with bronchiectasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BronchiectasisSputumAnti-Bacterial AgentsBacteriaHumansFemaleMaleMiddle AgedMicrobial Sensitivity TestsAdultAgedNorthern TerritoryDrug Resistance, BacterialYoung AdultRetrospective Studies

Stichwörter der Autor:innen

antibioticsbacterial infectionsempirical antibioticsexacerbationsmicroorganismpulmonary

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Faculty of Health, Charles Darwin University, Darwin, NT, Australia.
  • Darwin Respiratory and Sleep Health, Darwin Private Hospital, Darwin, NT, Australia.
  • Department of Respiratory and Sleep Medicine, Royal Darwin Hospital, Darwin, NT, Australia.
  • Infection Management Services, Princess Alexandra Hopsital, Metro South Hospital and Health Service, Brisbane, QLD, Australia.
  • College of Medicine and Public Health, Flinders University, Darwin, NT, Australia.
  • Australian Bronchiectasis Consortium, Lung Foundation, Brisbane, QLD, Australia.

ORCID-Profile: Subash S Heraganahally

Förderung

  • Thoracic Society of Australia and New Zealand (TSANZ) Robert Pierce Grant-In-Aid for Indigenous Lung Health

Zitieren

APA

Howarth, T., Castro, A., Kirojan, D., O'Connor, A., Campbell, S., & Heraganahally, S. S. (2026). Sputum antimicrobial susceptibility patterns and clinical outcomes among adult Aboriginal Australians with bronchiectasis. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666261480883

Vancouver

Howarth T, Castro A, Kirojan D, O'Connor A, Campbell S, Heraganahally SS. Sputum antimicrobial susceptibility patterns and clinical outcomes among adult Aboriginal Australians with bronchiectasis. Therapeutic Advances in Respiratory Disease. 2026. doi:10.1177/17534666261480883

BibTeX
@article{Howarth2026,
  author = {Howarth, Timothy and Castro, Angelou and Kirojan, Debora and O'Connor, Alison and Campbell, Stuart and Heraganahally, Subash S},
  title = {Sputum antimicrobial susceptibility patterns and clinical outcomes among adult Aboriginal Australians with bronchiectasis},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  doi = {10.1177/17534666261480883}
}
Kostenlos starten →